Navigation Links
CareFusion Reports First Quarter Results, Raises Full-Year Outlook
Date:11/5/2009

t per share amounts) 2009 2008 --------------------------------------------------------------------- Revenue $923 $915 Cost of Products Sold 472 478 --- --- Gross Margin 451 437 Selling, General and Administrative Expenses 297 280 Research and Development Expenses 36 37 Restructuring and Acquisition Integration Charges 1 30 --- --- Operating Income 117 90 Interest Expense and Other, Net 42 32 --- --- Income Before Income Taxes 75 58 Provision for Income Taxes 20 28 --- --- Income from Continuing Operations 55 30 Income from Discontinued Operations, Net of Tax 26 83 --- --- Net Income $81 $113 ==== ==== Per Share Amounts: (1) Basic Earnings per Common Share Continuing Operations $0.25 $0.14 Discontinued Operations $0.12 $0.38 Basic Earnings per Common Share $0.37 $0.51 Diluted Earnings per Common Share Continuing Operations
'/>"/>
SOURCE CareFusion Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
2. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
3. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
4. CareFusion Moves First Quarter Earnings Announcement to November 5
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq:...of-carebloodanalysissystems,announcedtodaythatClin...sentatthe21stAnnualPiperJaffrayHealthCareConferenc...ncewillbeheldattheNewYorkPalaceHotelinNewYorkCity....uresandmarketsportablebloodanalysissystemsforusein...
(Date:11/25/2009)...v.25/PRNewswire/--AccordingtoMillenniumResearchGro...tintelligence,thenearly$3billionUSmarketfortraumaf...extfiveyearsdespitetherecenteconomicslowdown.MRG,s...ismarketwillremainhighlydynamicoverthenextfiveyear...eviouslyunderservedsegmentsofthetraumafixationmark...
(Date:11/25/2009)...Nov.25/PRNewswire/--CempraPharmaceuticalsInc.today...fexecutiveofficer,willpresentatthePiperJaffray21st...2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Ferna...ntibioticclinicalprogramsforthetreatmentofdrug-res...armaceuticals ,, Foundedin2006,CempraPharmaceu...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Cancer Advocacy Organization Confronts the Source of rBGH Demands Pharmaceutical Giant Eli Lilly Stop Milking Cancer 57914 1Cancer Advocacy Organization Confronts the Source of rBGH Demands Pharmaceutical Giant Eli Lilly Stop Milking Cancer 57914 2Will Jatropha Become a 26apos 3BDotCom Bubble 26apos 3B in Biofuel Industry 3F Leading to 2nd JatrophaWorld Africa Jatropha Webinar on 30 Sept 09 Ex 14196 1Will Jatropha Become a 26apos 3BDotCom Bubble 26apos 3B in Biofuel Industry 3F Leading to 2nd JatrophaWorld Africa Jatropha Webinar on 30 Sept 09 Ex 14196 2Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 1Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 2Brain Aneurysm Patients Have A New Voice With Brain Storms Blog 57908 3
.../ -- Asenapine -- an,investigational drug being de...unit of Akzo Nobel, for bipolar I disorder and,sch...e than placebo,in treating acute manic and mixed e...ing to new Phase III results, from a study,present...Annual,Meeting. , In the three-week study, patient...
... -, COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-Fi...afety and efficacy of,desvenlafaxine succinate, a ... being studied as a potential treatment for adults...ted today at the,2007 American Psychiatric Associa... Pharmaceuticals, a division of Wyeth . Results,fr...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:11/25/2009)...elleMedicalInc.,aleadingmanufacturerofbreastMRIcoi...newleadingedgeclinicalapplicationsonitsAegis(TM)me...alSocietyofNorthAmerica(RSNA)annualmeetinginChicag...nsleveragetheuniquehighqualityimagesgeneratedbySen...pleimagingmodalitiesformulti-parametricassessment....
(Date:11/25/2009)...TheBayAreaAirQualityManagementDistrictisissuingthe...rt forThursday,November26,2009whichbansburningwo...oorsandoutdoors. ,, "Cold,stillweatherwillcontr...ent,executiveofficeroftheAirDistrict."We,reaskingB...ndfellowcommunitymembersthisThanksgiving,andnottob...
(Date:11/25/2009)...of a collaboration between UCLA engineers and phys...10 million Americans who suffer from peripheral ar... the arteries, peripheral arterial disease, or PAD...d arteries reduce blood flow to the limbs. The con...se, heart attack and stroke, and its progression c...
(Date:11/25/2009)...treatment clinics to resume Monday, Nov. 30 , ..., 2009 -- Centegra Health System is continuing to ...t four Centegra Primary Care (CPC) vaccination cli.... The clinics are at CPC sites in Huntley, Woodsto...ollows: ,   From 4:30 to 7:30 p.m. Tue...
(Date:11/25/2009)...IONSkincare ®isproudtosupportGNC,seffortstora...St.Jude ThanksandGiving campaign,$1fromthepurchase...pBalm willbedonatedtoSt.Jude.Additionally,GNCcusto...heckoutatoneoftheir5,000+retaillocationsoratGNC.co...their2009 ThanksandGiving campaign. ,, "Wearede...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
... hormone released during act reinforces maternal b...- Mothers who breast-feed are less likely to negle..., In their study, the scientists followed 7,223 Au...reast-fed for less than four months were twice as ...
...ith a particular gene variant may be more likely t...n people without the gene, according to a study pu...eurology , the medical journal of the American Aca...rme, the most common type of brain cancer. People ...
... having a private well or septic system, and other... risk factors for bacterial intestinal infections ...o food, such as the current Salmonella outbreak ...ically termed as enteric infections. The new study...
...eased 19% to $80.8 Million and EPS Increased to $1...k Repurchase Program for up to One Million Shares ...ves, Inc. (Nasdaq: MTXX ), a healthcare company ...its fiscal 2009 third quarter and nine months ende...
...ing to its strong executive team, Halo Pharmaceuti...ston, a thirty-five year pharmaceutical industry v...evelopment. Al comes to Halo from a long and dist...n of Al to the Halo business development team is a...
...e, third of popular sweetened products showed trac... Almost half of tested samples of commercial high-...h was also found in nearly a third of 55 popular b...aced sugar as the sweetener in many beverages and ...
Other Medicine News:Health News:Moms Who Breast-Feed Less Likely to Neglect Child 2Health News:Was it the chicken salad or the swim? 2Health News:Was it the chicken salad or the swim? 3Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 2Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 3Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 4Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 5Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 6Health News:Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share 7Health News:Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business Development 2Health News:Study Finds High-Fructose Corn Syrup Contains Mercury 2
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: